What is the recommended dosing regimen of apixaban for treatment and prophylaxis of venous thromboembolism in adults, including adjustments for age, weight, and renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Apixaban Dosing for Venous Thromboembolism

For acute VTE treatment, start apixaban 10 mg orally twice daily for the first 7 days, then reduce to 5 mg twice daily for continued treatment. 1

Initial Treatment Phase (First 7 Days)

  • Dose: 10 mg orally twice daily
  • Duration: Exactly 7 days
  • No dose adjustment needed for age, weight, or renal function during this acute phase 2, 3, 1

This higher initial dose provides rapid therapeutic anticoagulation without requiring parenteral bridging therapy (unlike dabigatran or edoxaban), which is a key advantage 4.

Maintenance Treatment Phase (After 7 Days)

  • Dose: 5 mg orally twice daily
  • Duration: Minimum 3 months for provoked VTE; 6 months for unprovoked VTE 2, 3
  • No dose reduction criteria exist for VTE treatment based on age, weight, or renal function 5, 6

Critical pitfall: Do NOT apply the atrial fibrillation dose reduction criteria (age ≥80 years, weight ≤60 kg, creatinine ≥1.5 mg/dL) to VTE patients. 5 This is the most common prescribing error with apixaban, leading to inappropriate underdosing in up to 40% of cases. The VTE indication requires full-dose therapy regardless of these factors.

Extended/Secondary Prevention (After ≥6 Months)

After completing at least 6 months of full-dose treatment, reduce to 2.5 mg orally twice daily for extended prophylaxis against recurrent VTE. 2, 7, 1

This reduced dose is appropriate for:

  • Patients requiring indefinite anticoagulation
  • Those with unprovoked VTE or persistent risk factors
  • Cancer-associated VTE after initial treatment phase 8, 9

The 2.5 mg twice daily dose provides effective secondary prevention with significantly lower bleeding rates compared to continuing 5 mg twice daily, particularly in cancer patients (12.1% vs 15.6% clinically relevant bleeding). 8

Renal Function Considerations

Unlike atrial fibrillation, there are NO FDA-approved dose reductions for apixaban in VTE based on renal function alone. 1, 6

  • CrCl >30 mL/min: Use standard VTE dosing
  • CrCl 15-29 mL/min: Not studied; use with extreme caution or consider alternative (LMWH preferred)
  • CrCl <15 mL/min or dialysis: Avoid apixaban 10

Special Populations

Cancer patients: Use the same dosing regimen (10 mg BID × 7 days → 5 mg BID). 3 Apixaban is preferred over LMWH for most cancer-associated VTE, except in patients with gastric or gastroesophageal tumors where bleeding risk is substantially higher with DOACs. 3 In these cases, LMWH remains preferred.

Drug interactions: Reduce dose by 50% when combined P-gp and strong CYP3A4 inhibitors (ketoconazole, ritonavir, itraconazole) are used. 1 If already on 2.5 mg BID, avoid these combinations entirely.

Obesity: No dose adjustment needed regardless of BMI or weight. 11

VTE Prophylaxis Post-Surgery

For orthopedic surgery prophylaxis only:

  • Dose: 2.5 mg orally twice daily
  • Start: 12-24 hours post-surgery
  • Duration: 35 days (hip replacement) or 12 days (knee replacement) 1

Key Clinical Pearls

The AMPLIFY trial 4 demonstrated that this fixed-dose regimen (10 mg BID × 7 days → 5 mg BID) was noninferior to enoxaparin/warfarin for VTE treatment with 69% less major bleeding (0.6% vs 1.8%, P<0.001).

Avoid these common errors:

  1. Reducing to 2.5 mg BID too early (must complete ≥6 months at 5 mg BID first)
  2. Applying atrial fibrillation dose reduction criteria to VTE patients
  3. Dose reducing for "perceived bleeding risk" without meeting specific criteria 5
  4. Using apixaban in gastric/gastroesophageal cancer without careful consideration 3

Timing of doses: If a dose is missed, take as soon as remembered on the same day, then resume twice-daily schedule. Never double the dose. 1

References

Guideline

cancer-associated venous thromboembolic disease, version 2.2024, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2024

Research

Oral apixaban for the treatment of acute venous thromboembolism.

The New England journal of medicine, 2013

Research

Venous thromboembolism: current management.

Australian prescriber, 2019

Guideline

venous thromboembolic disease.

Journal of the National Comprehensive Cancer Network : JNCCN, 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.